期刊
JOURNAL OF ORGANIC CHEMISTRY
卷 76, 期 17, 页码 7048-7055出版社
AMER CHEMICAL SOC
DOI: 10.1021/jo200958a
关键词
-
Cortisol and the glucocorticoid receptor (GR) signaling pathway has been linked to the development of diabetes and metabolic syndrome. In vivo, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSDI) catalyzes the conversion of inactive cortisone to its active form, cortisol. Existing clinical data have supported 11 beta-HSDI as a valid therapeutic target for type 2 diabetes. In our research program, (R)-1,1,1-trifluoro-2-(3-((R)-4-(4-fluoro-2- (trifluoromethyl)phenyl)-2-methylpiperazin-1-ylsulfonyl)phenyl)propan-2-ol (HSD-016) was discovered to be a potent, selective, and efficacious 11 beta-HSDI inhibitor and advanced as a clinical candidate. Herein, a reliable and scalable synthesis of HSD-016 is described. Key transformations include an asymmetric synthesis of a chiral tertiary alcohol via Sharpless dihydroxylation, epoxide formation, and subsequent mild reduction. This route ensured multikilogram quantities of HSD-016 necessary for clinical studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据